Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, Nicole Tilton & Maria Roberta Cilio CNS Drugs, 2018 DOI : 10.1007/s40263-018-0589-2 Abstract Background : Purified cannabidiol is a new antiepileptic drug that has recently been approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most published studies have not extended beyond 12–16 weeks. Objective : The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy. Methods : Patients aged 1–17 years with refractory epilepsy were enrolled in an open-label [...]
Lire la suiteNeurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018 : Responders Versus Nonresponders Eef L. Theunissen, Nadia R.P.W. Hutten, Natasha L. Mason, Stefan W. Toennes, Kim P.C. Kuypers, and Johannes G. Ramaekers Cannabis and Cannabinoid Research, Volume 4, Number 1, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0047 Abstract Introduction : Synthetic cannabinoid mixtures have been easily accessible for years, leading to the belief that these products were natural and harmless, which contributed to their popularity. Nevertheless, there are many reports of users ending up in hospital due to severe side effects such as tachycardia, aggression, and psychosis. Controlled studies on the effects of synthetic cannabinoids on [...]
Lire la suiteCannabis‐based products for pediatric epilepsy : A systematic review Jesse Elliott, Deirdre DeJean, Tammy Clifford, Doug Coyle, Beth K. Potter, Becky Skidmore, Christine Alexander, Alexander E. Repetski, Vijay Shukla, Bláthnaid McCoy, George A. Wells, Epilepsia, 2018, 1-14. DOI: 10.1111/epi.14608 Summary Objective : To assess the benefits and harms of cannabis‐based products for pediatric epilepsy. Methods : We identified in this living systematic review randomized controlled trials (RCTs) and nonrandomized studies (NRSs) involving children with epilepsy treated with cannabis‐based products. We searched MEDLINE, Embase, PsycINFO, Cochrane Library, and gray literature (April 25, 2018). The primary outcome was seizure freedom; secondary outcomes were seizure frequency (total, ≥50% reduction), quality of life, sleep, status epilepticus, death, gastrointestinal adverse [...]
Lire la suite